Multiple sclerosis and related disordersHumansMaleFemaleAdultBortezomib
Experience of bortezomib use in refractory autoimmune neurological disorders.
Ekaterina Popova, Sudheeran Kannoth, Venkitesh Girish, Jeeva Premaja Jiju, Saraf Udit Umesh, Gopikrishnan Unnikrishnan, Siby Gopinath, Vivek Nambiar, Anandkumar Anandakuttan
Published: 202610.1016/j.msard.2025.106870
Abstract
BACKGROUND: Bortezomib (BTZ) is a proteasome inhibitor depleting plasma cells. We share experience of BTZ use in patients with refractory autoimmune-mediated neurological disorders and its safety characteristics. METHODS: This single-center (AIMS, Ko…
Preview only. Read the full abstract at the source